What is the Tatva Chintan Pharma Chem PE ratio today?
Tatva Chintan Pharma Chem's PE ratio is 60.0 at the previous close (₹1,614.80 a share): a market capitalisation of ₹3,777 crore divided by consolidated net profit of ₹62.9 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹42.1 crore) it is 89.8.
What is the Tatva Chintan Pharma Chem PB ratio (price to book value)?
Tatva Chintan Pharma Chem's price-to-book (PB) ratio is 4.64 at the previous close: a market capitalisation of ₹3,777 crore divided by shareholders' equity (book value) of ₹815 crore on 30 September 2026. That is a book value of ₹348.26 per share against a share price of ₹1,614.80.
What is the Tatva Chintan Pharma Chem book value per share?
Tatva Chintan Pharma Chem's book value per share was ₹348.26 on 30 September 2026: shareholders' equity of ₹815 crore divided by the 2.34 crore shares in issue, up 8.0% from ₹322.50 a year earlier. The share price at the previous close was ₹1,614.80.
What is the Tatva Chintan Pharma Chem market cap?
Tatva Chintan Pharma Chem's market capitalisation was ₹3,777 crore at the previous close: 2.34 crore shares at ₹1,614.80 each.
Is Tatva Chintan Pharma Chem debt free?
No. Tatva Chintan Pharma Chem had borrowings of ₹170 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.21. Its cash and current investments were ₹15.2 crore, so its net debt was ₹155 crore.
What is the Tatva Chintan Pharma Chem EPS?
Tatva Chintan Pharma Chem's basic earnings per share (EPS) were ₹17.98 in FY26, against ₹2.44 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹26.90.
What is the Tatva Chintan Pharma Chem debt to equity ratio?
Tatva Chintan Pharma Chem's debt-to-equity ratio was 0.21 on 30 September 2026: borrowings of ₹170 crore against total equity of ₹815 crore. A year earlier, on 30 September 2025, it was 0.11.
What is the Tatva Chintan Pharma Chem dividend yield?
Tatva Chintan Pharma Chem's dividend yield is 0.12% at the previous close: dividends of ₹2 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹1,614.80. They were ₹2 on 11 September 2026.
What is the Tatva Chintan Pharma Chem promoter holding?
Promoters held 72.02% of Tatva Chintan Pharma Chem on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the Tatva Chintan Pharma Chem net worth?
Tatva Chintan Pharma Chem's net worth — shareholders' equity in its consolidated balance sheet — was ₹815 crore on 30 September 2026, up 8.0% from ₹754 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹3,777 crore at the previous close.
What is the Tatva Chintan Pharma Chem ROE and ROCE?
In FY26, Tatva Chintan Pharma Chem's return on equity (ROE) was 5.5% and its return on capital employed (ROCE) was 7.4%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 0.8% and ROCE 0.9%.
What is the Tatva Chintan Pharma Chem shareholding pattern?
On 30 September 2026, Tatva Chintan Pharma Chem's shares were held by promoters 72.02%, foreign portfolio investors (FII/FPI) 4.38%, domestic institutions (DII) 3.21% (including mutual funds at 2.87%) and retail and other non-institutional investors 20.39%. Over the year, FII holding was up 0.99 percentage points from 3.39% and DII holding was down 0.65 percentage points from 3.86%.
What is the Tatva Chintan Pharma Chem dividend in 2026 and its record date?
In 2026, Tatva Chintan Pharma Chem has declared one dividend: ₹2 with record date 11 September 2026.
What is the Tatva Chintan Pharma Chem free cash flow?
In FY26, Tatva Chintan Pharma Chem generated ₹31.5 crore of cash from operations and spent ₹114 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹82.3 crore. In FY25 it was −₹51.6 crore.
What are the Tatva Chintan Pharma Chem latest quarterly results?
Tatva Chintan Pharma Chem's latest results are for Q2 FY27 (July–September 2026), filed on 19 October 2026: consolidated net profit ₹21.5 crore, up 116.3% from ₹9.9 crore in Q2 FY26; revenue from operations ₹217 crore, up 75.9% year on year.
What is the Tatva Chintan Pharma Chem revenue and profit in FY26?
In FY26 (April 2025–March 2026), Tatva Chintan Pharma Chem's consolidated net profit was ₹42.1 crore, up 636.1% from ₹5.7 crore in FY25, on revenue from operations of ₹506 crore (up 32.2%). Over three years, from FY23, net profit was down 7.5%.
When are the Tatva Chintan Pharma Chem next results?
Tatva Chintan Pharma Chem has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
Tatva Chintan Pharma Chem vs Vishnu Chemicals: how do they compare?
In FY26, Tatva Chintan Pharma Chem earned net profit of ₹42.1 crore on revenue of ₹506 crore, against ₹142 crore on ₹1,610 crore for Vishnu Chemicals. Tatva Chintan Pharma Chem's operating margin was 11.1% (Vishnu Chemicals 13.1%) and its return on equity 5.5% (Vishnu Chemicals 14.3%).
How does Tatva Chintan Pharma Chem compare with its peers?
On FY26 consolidated figures, against Vishnu Chemicals, Jubilant Agri and Consumer Products and Kiri Industries: Tatva Chintan Pharma Chem's operating margin of 11.1% is the second highest of the four (Vishnu Chemicals 13.1%, Jubilant Agri and Consumer Products 9.4%, Kiri Industries −31.9%; peer average −3.1%); its return on equity of 5.5% is the lowest of the four (Vishnu Chemicals 14.3%, Jubilant Agri and Consumer Products 32.6%, Kiri Industries 115.0%; peer average 53.9%).
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
